189 related articles for article (PubMed ID: 1657425)
21. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
[TBL] [Abstract][Full Text] [Related]
22. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
23. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Stahl M; Kasimir-Bauer S; Harstrick A
Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
26. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
27. Combined modalities of resistance in etoposide-resistant human KB cell lines.
Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
[TBL] [Abstract][Full Text] [Related]
28. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of type II topoisomerase by fostriecin.
Boritzki TJ; Wolfard TS; Besserer JA; Jackson RC; Fry DW
Biochem Pharmacol; 1988 Nov; 37(21):4063-8. PubMed ID: 2847752
[TBL] [Abstract][Full Text] [Related]
30. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
Funayama Y; Nishio K; Takeda Y; Kubota N; Ohira T; Ohmori T; Ohta S; Ogasawara H; Hasegawa S; Saijo N
Anticancer Res; 1993; 13(6A):1981-8. PubMed ID: 8297104
[TBL] [Abstract][Full Text] [Related]
31. A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance.
Hospers GA; Meijer C; de Leij L; Uges DR; Mulder NH; de Vries EG
Int J Cancer; 1990 Jul; 46(1):138-44. PubMed ID: 2163989
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
[TBL] [Abstract][Full Text] [Related]
33. In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II.
Aoyagi Y; Kobunai T; Utsugi T; Oh-hara T; Yamada Y
Jpn J Cancer Res; 1999 May; 90(5):578-87. PubMed ID: 10391099
[TBL] [Abstract][Full Text] [Related]
34. Effect of topoisomerase poisoning by antitumor drugs VM 26, fostriecin and camptothecin on DNA repair replication by mammalian cell extracts.
Frosina G; Rossi O
Carcinogenesis; 1992 Aug; 13(8):1371-7. PubMed ID: 1323426
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermic potentiation of cisplatin toxicity in a human small cell lung carcinoma cell line and a cisplatin resistant subline.
Hettinga JV; Lemstra W; Meijer C; Mulder NH; Konings AW; de Vries EG; Kampinga HH
Int J Hyperthermia; 1994; 10(6):795-805. PubMed ID: 7884239
[TBL] [Abstract][Full Text] [Related]
37. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
Multon E; Riou JF; LeFevre D; Ahomadegbe JC; Riou G
Biochem Pharmacol; 1989 Jul; 38(13):2077-86. PubMed ID: 2544183
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
[TBL] [Abstract][Full Text] [Related]
39. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
Meijer C; Mulder NH; Hospers GA; Uges DR; de Vries EG
Br J Cancer; 1990 Jul; 62(1):72-7. PubMed ID: 2390486
[TBL] [Abstract][Full Text] [Related]
40. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
